Worth reading
61In focus
Scored from 3 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
230
Millions of yenWording
Conditional
How definitive the wording is.Contents of this document
Financial Results PresentationNine months ended March 20266 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales230 Millions of yen
Operating profit-345 Millions of yen
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Milestone revenue related to SMD106Amount100 Millions of yenDetailsRevenue recognized in Q3
- Growth in the DTx Platform Business
New initiatives
- Submission of a request for insurance coverage and formulation of a sales plan ahead of the launch of the insomnia disorder treatment app
- Initiation of a confirmatory trial for SMD403, an app for treating tinnitus
- Conduct of an exploratory trial for SMD105, an app for post-mastectomy pain syndrome
- Commencement of provision of a clinical trial system for Heartseed’s company-sponsored clinical trial
Key KPIsA metric the company considers important as a management benchmark.
- Number of development pipeline projects12 Engagements
- Number of contracted projects15 Engagements
- Number of patents obtained31 Engagements
- Cumulative number of projects adopted21 Engagements
- Cumulative number of joint research collaborations24 Companies/institutions
Segment results
- DTx product businessBusiness profitability100 Millions of yenSegment profit-56 Millions of yen
- DTx platform businessBusiness profitability130 Millions of yenSegment profit76 Millions of yen
Market Size / Share
- Target market size for apps treating insomnia disorders¥1,000 million
- Potential market size for apps treating insomnia disorders¥3,500 million
- SAM for apps treating insomnia disorders400 over ¥ hundred million
Number of employees
Number of Employees49 People
As ofAs of May 2026
| Item | Details |
|---|---|
| Document type | Financial Results Presentation |
| Fiscal Period Covered | Nine months ended March 2026 |
| Net Sales | 230 Millions of yen |
| Operating profit | -345 Millions of yen |
| Segment results | Segment DTx product business / Business profitability 100 Millions of yen / Segment profit -56 Millions of yen / Year on year against the same period last year Not disclosed, Segment DTx platform business / Business profitability 130 Millions of yen / Segment profit 76 Millions of yen / Year on year against the same period last year Not disclosed |
| Breakdown of Factors Affecting the Change | Factors Milestone revenue related to SMD106 / Amount 100 Millions of yen / Details Revenue recognized in Q3, Factors Growth in the DTx Platform Business / Amount Not disclosed |
| Key KPIs | Indicator name Number of development pipeline projects / Value 12 Engagements / Year on year against the same period last year Not disclosed, Indicator name Number of contracted projects / Value 15 Engagements / Year on year against the same period last year Not disclosed, Indicator name Number of patents obtained / Value 31 Engagements / Year on year against the same period last year Not disclosed, Indicator name Cumulative number of projects adopted / Value 21 Engagements / Year on year against the same period last year Not disclosed, Indicator name Cumulative number of joint research collaborations / Value 24 Companies/institutions / Year on year against the same period last year Not disclosed |
| Number of employees | Number of Employees 49 People / As of As of May 2026 / Change during the period Not disclosed / Hiring plan Not disclosed |
| Market Size / Share | Subject Target market size for apps treating insomnia disorders / Value ¥1,000 million, Subject Potential market size for apps treating insomnia disorders / Value ¥3,500 million, Subject SAM for apps treating insomnia disorders / Value 400 over ¥ hundred million |
| New initiatives | Submission of a request for insurance coverage and formulation of a sales plan ahead of the launch of the insomnia disorder treatment app, Initiation of a confirmatory trial for SMD403, an app for treating tinnitus, Conduct of an exploratory trial for SMD105, an app for post-mastectomy pain syndrome, Commencement of provision of a clinical trial system for Heartseed’s company-sponsored clinical trial |
Items this document does not state (21)
Ordinary incomeNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company attributed business revenue to “the contribution from milestone revenue and growth in the DTx platform.” The parties agreed to advance SMD106 to the next stage of development, and ¥100 million in milestone revenue was recognized in Q3. The company also stated that there had been no significant change in its cost structure in relation to the operating loss.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.